NYSE: PFEPfizer Inc Stock
$30.47+0.39 (+1.3%)
Updated Nov 30, 2023
Pfizer shares are trading lower... find out Why PFE Price Moved with a free WallStreetZen account
Why Price MovedPFE Price
$30.47
Fair Value Price
N/A
Market Cap
$172.05B
52 Week Low
$28.93
52 Week High
$54.93
P/E
16.47x
P/B
1.77x
P/S
2.73x
PEG
0.62x
Dividend Yield
5.38%
Revenue
$68.54B
Earnings
$10.48B
Gross Margin
60.5%
Operating Margin
15.16%
Profit Margin
15.3%
Debt to Equity
1.22
Operating Cash Flow
$12B
Beta
0.58
Next Earnings
Jan 29, 2024
Ex-Dividend
Nov 9, 2023
Next Dividend
Dec 4, 2023
PFE Overview
Pfizer Inc. develops and manufactures medicines and vaccines in many therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands, biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands, and sterile injectable and anti-infective medicines and oral COVID-19 treatment under the Sulperazon, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. Pfizer was founded in 1849 and is headquartered in New York, NY.
Zen Score
–
Industry Average (42)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PFE scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PFE ($30.47) is trading above its intrinsic value of $25.98, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PFE is good value based on its earnings relative to its share price (16.47x), compared to the US market average (29.24x)
P/E vs Market Valuation
PFE is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more PFE due diligence checks available for Premium users.
Be the first to know about important PFE news, forecast changes, insider trades & much more!
PFE News
Valuation
PFE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
16.47x
Industry
43.24x
Market
29.24x
PFE is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
PFE is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
PFE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.77x
Industry
5.34x
PFE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PFE price to earnings growth (PEG)
For valuing profitable companies with growth potential
PFE is good value based... subscribe to Premium to read more.
PEG Value Valuation
PFE's financial health
Profit margin
Revenue
$13.2B
Net Income
-$2.4B
Profit Margin
-18%
PFE's Earnings (EBIT) of $10.39B... subscribe to Premium to read more.
Interest Coverage Financials
PFE's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$215.0B
Liabilities
$117.8B
Debt to equity
1.22
PFE's short-term assets ($74.01B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PFE's long-term liabilities ($86.68B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PFE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PFE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$3.5B
Investing
$888.0M
Financing
-$3.8B
PFE's operating cash flow ($12.04B)... subscribe to Premium to read more.
Debt Coverage Financials
PFE vs General Drug Manufacturer Stocks
Pfizer Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.